National Lung Cancer Audit annual report 2018 | The Healthcare Quality Improvement Partnership
This report represents the culmination of nearly two years of patient care and follow up, data collection, data analysis and interpretation. Its purpose is to understand the current quality of care and outcomes for patients with lung cancer, to celebrate good practice and to highlight variability, to ensure that all patients have access to the best care.
The results demonstrate improving data quality, higher rates of surgical treatment, and higher rates of systemic anti-cancer treatment across both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), such that four out of our five key auditable measures have been achieved. Additionally, continuing improvements in data completeness can be observed with 85% completeness seen for performance status (PS), 96% for stage and 64% for recording of lung function in patients potentially suitable for curative treatment, as compared to 82%, 96% and 56% respectively in the previous reporting period.
NICE | April 2019 | Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Technology appraisal guidance [TA578]
Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
More evidence on durvalumab is being collected, until September 2021. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
NICE | March 2019 | Lung cancer: diagnosis and management NICE guideline
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up (Source: NICE).
NICE | March 2019 | Promising lung cancer treatment approved for Cancer Drugs Fund
NICE has unveiled a promising lung cancer treatment has been approved for the Cancer Drugs Fund, as a result of a NICE recommendation. Today NICE has published draft final guidance.
Durvalumab helps the body’s immune system to find and attack cancer cells, by blocking the PD-L1 protein which disguises cancer.
In a clinical trial people taking it went for an average of around 2 years without the disease progressing, versus 6 months for those without. The committee agreed that it was plausible that between 27% and 40% of people taking durvalumab would have 5 years of progression-free survival.